

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

Pr **NERLYNX**[®]

Neratinib Tablets

40 mg neratinib (as neratinib maleate), Oral

Protein Kinase Inhibitor (L01XE45)

Knight Therapeutics Inc.
3400 De Maisonneuve W., Suite 1055
Montreal, QC
Canada H3Z 3B8

Date of Initial Authorization:
July 15, 2019

Date of Revision:
July 16, 2021

Submission Control No: 249980

NERLYNX[®] is a registered trademark of Puma Biotechnology, Inc., used under license to Knight Therapeutics Inc.

RECENT MAJOR LABEL CHANGES

1 Indications	06/2021
1 Indications, 1.2 Geriatrics	06/2021
4 Dosage and Administration, 4.1 Dosing Considerations	07/2021
4 Dosage and Administration, 4.2 Recommended Dose and Dosage Adjustment	07/2021
7 Warnings and Precautions	07/2021
7 Warnings and Precautions, 7.1.4 Geriatrics	06/2021

TABLE OF CONTENTS

PART I: HEALTH PROFESSIONAL INFORMATION	4
1 INDICATIONS	4
1.1 Pediatrics	4
1.2 Geriatrics	4
2 CONTRAINDICATIONS	4
4 DOSAGE AND ADMINISTRATION	4
4.1 Dosing Considerations	4
4.2 Recommended Dose and Dosage Adjustment	6
4.4 Administration	10
4.5 Missed Dose	10
5 OVERDOSAGE	11
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING	11
7 WARNINGS AND PRECAUTIONS	11
7.1 Special Populations	14
7.1.1 Pregnant Women	14
7.1.2 Breast-feeding	14
7.1.3 Pediatrics	14
7.1.4 Geriatrics	14
8 ADVERSE REACTIONS	15
8.1 Adverse Reaction Overview	15
8.2 Clinical Trial Adverse Reactions	17
8.3 Less Common Clinical Trial Adverse Reactions	20
8.4 Abnormal Laboratory Findings: Hematological, Clinical, Chemistry and Other Quantitative Data	21
9 DRUG INTERACTIONS	22
9.2 Drug Interactions Overview	22
9.4 Drug-Drug Interactions	22
9.5 Drug-Food Interactions	25
9.6 Drug-Herb Interactions	25
10 CLINICAL PHARMACOLOGY	25
10.1 Mechanism of Action	25

10.2	Pharmacodynamics	25
10.3	Pharmacokinetics.....	26
11	STORAGE, STABILITY AND DISPOSAL	28
12	SPECIAL HANDLING INSTRUCTIONS.....	28
PART II: SCIENTIFIC INFORMATION		29
13	PHARMACEUTICAL INFORMATION	29
14	CLINICAL TRIALS	30
14.1	Clinical Trials by Indication.....	30
15	MICROBIOLOGY.....	38
16	NON-CLINICAL TOXICOLOGY.....	38
PATIENT MEDICATION INFORMATION.....		41

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

NERLYNX (neratinib) is indicated:

- For the extended adjuvant treatment of women with early-stage hormone receptor positive and HER2-overexpressed/amplified breast cancer, within one year after completion of trastuzumab-based adjuvant therapy.
- In combination with capecitabine for the treatment of patients with metastatic HER2-overexpressed/amplified breast cancer, who have received two or more prior anti-HER2-based regimens in the metastatic setting.

1.1 Pediatrics

Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

1.2 Geriatrics

Geriatrics (≥ 65 years of age): In the Phase 3 study conducted in the extended adjuvant setting (ExteNET), a total of 1408 patients received NERLYNX of whom 24.9% were ≥ 60 years of age. Lower magnitude of efficacy was noted in patients of ≥ 60 years when compared to patients of < 60 years of age. Some differences in the clinical safety have been identified between the elderly and younger subjects (see 7 WARNINGS AND PRECAUTIONS, 7.1.4 Geriatrics).

In the Phase 3 study conducted in the metastatic setting (NALA), a total of 303 patients received NERLYNX in combination with capecitabine, of whom 20.5% were ≥ 65 years of age. No overall differences of efficacy were observed between patients ≥ 65 years when compared to patients of < 65 years of age. Some differences in the clinical safety have been identified between the elderly and younger subjects (see 7 WARNINGS AND PRECAUTIONS, 7.1.4 Geriatrics).

2 CONTRAINDICATIONS

NERLYNX is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

NERLYNX treatment can cause severe diarrhea (see 7 WARNINGS AND PRECAUTIONS).

Either a NERLYNX dose escalation or antidiarrheal prophylaxis with loperamide is recommended to lower the incidence and severity of diarrhea (see 8 ADVERSE REACTIONS and 7 WARNINGS AND PRECAUTIONS). NERLYNX dose interruptions or dose reductions may also be required to manage diarrhea (see 4.2 Recommended Dose and Dosage Adjustment).

Prophylaxis Management of Diarrhea

DOSE ESCALATION PROPHYLAXIS

Initiate NERLYNX at 120 mg daily and increase the dose according to the treatment schedule described in Table 1.

Table 1. NERLYNX Dose Escalation and Treatment Schedule

Time on NERLYNX	NERLYNX Dose
Week 1 (days 1–7)	120 mg daily (three 40 mg tablets)
Week 2 (days 8–14)	160 mg daily (four 40 mg tablets)
Week 3 and onwards	240 mg daily (six 40 mg tablets, recommended dose)

If diarrhea occurs with dose escalation, loperamide 4 mg should be initiated no later than with the first bout of diarrhea, and continued with loperamide 2 mg after every subsequent loose stool, up to 16 mg per day, until diarrhea-free for 12 hours. Then, titrate loperamide to keep diarrhea controlled (1-2 bowel movements per day).

ANTIDIARRHEAL PROPHYLAXIS WITH LOPERAMIDE

Administer loperamide during the first 56 days of treatment, starting with the first dose of NERLYNX.

For both indications, instruct patients to take loperamide as directed in Table 2, titrating to 1-2 bowel movements per day. Additional antidiarrheal agents may be required to manage diarrhea in patients with loperamide-refractory diarrhea (see Tables 6 and 7 below).

Table 2. Loperamide Prophylaxis

Time on NERLYNX	Dose	Frequency*
Weeks 1-2 (days 1–14)	4 mg	Three times daily
Weeks 3-8 (days 15–56)	4 mg	Twice daily
Weeks 9 and onwards	4 mg	As needed (not to exceed 16 mg per day)

Titrate dosing to achieve 1 – 2 bowel movements per day (not to exceed 16 mg per day)

4.2 Recommended Dose and Dosage Adjustment

Recommended Dose

Extended Adjuvant Treatment of Early-Stage Breast Cancer: The recommended dose of NERLYNX is 240 mg (six 40 mg tablets) given orally once daily with food, continuously for one year at approximately the same time every day.

NERLYNX should be used in combination with endocrine therapy in patients with early-stage hormone receptor-positive and HER2 overexpressed/amplified breast cancer within one year after completion of trastuzumab-based adjuvant therapy.

Metastatic Breast Cancer: The recommended dose of NERLYNX is 240 mg (six 40 mg tablets) given orally once daily with food, at approximately the same time on Day 1 – 21 of a 21-day cycle in combination with capecitabine on Day 1 – 14 of a 21-day cycle until disease progression or unacceptable toxicities.

The recommended dose of capecitabine is 1500 mg/m² total daily dose evenly divided into 2 doses of 750 mg/m² each, starting on cycle 1 Day 1. Capecitabine should be taken with food or within 30 minutes after a meal.

Dose Adjustment for Adverse Reactions

NERLYNX dose modification is recommended based on individual safety and tolerability. Management of some adverse reactions may require dose interruption and/or dose reduction of treatment with NERLYNX as shown in Tables 3 to 8 below. Discontinue NERLYNX in patients who fail to recover to Grade 0-1 from treatment-related toxicity, for toxicities that result in a treatment delay of > 3 weeks, or for patients who are unable to tolerate 120 mg NERLYNX daily. Additional clinical situations may result in dose adjustments as clinically indicated (e.g., intolerable toxicities, persistent Grade 2 adverse reactions, etc.).

When NERLYNX is used in combination with capecitabine, refer to the product monograph for dose modifications to capecitabine.

Table 3. NERLYNX Monotherapy Dose Modifications for Adverse Reactions

Dose Level	NERLYNX Dose
Recommended starting dose	240 mg daily
First dose reduction	200 mg daily
Second dose reduction	160 mg daily
Third dose reduction	120 mg daily

Table 4. NERLYNX in Combination with Capecitabine Dose Modification for Adverse Reactions

Dose Level	NERLYNX Dose
Recommended starting dose	240 mg daily
First dose reduction	160 mg daily
Second dose reduction	120 mg daily

Table 5. NERLYNX Dose Modifications and Management—General Toxicities*

Severity of Toxicity†	Action
Grade 3	Hold NERLYNX until recovery to Grade ≤ 1 or baseline within 3 weeks of stopping treatment. Then resume NERLYNX at the next lower dose level.
Grade 4	Discontinue NERLYNX permanently.

* Refer to Table 6, 7 and 8 below for management of diarrhea and hepatotoxicity

† Per CTCAE v4.0

Dose Modifications for Diarrhea

Diarrhea management requires the correct use of antidiarrheal medication, dietary changes, replacement of fluids and electrolytes and appropriate dose modifications of NERLYNX. Guidelines for adjusting doses of NERLYNX in patients presenting with diarrhea are shown in Tables 6 and 7.

Table 6. NERLYNX Monotherapy Dose Modifications for Diarrhea

Severity of Diarrhea*	Action
<ul style="list-style-type: none"> Grade 1 diarrhea [increase of < 4 stools per day over baseline] Grade 2 diarrhea [increase of 4-6 stools per day over baseline] lasting < 5 days Grade 3 diarrhea [increase of ≥ 7 stools per day over baseline; incontinence; hospitalization indicated; limiting self-care activities of daily living] lasting ≤ 2 days 	<ul style="list-style-type: none"> Adjust antidiarrheal treatment Diet modifications Fluid intake of ~2 L should be maintained to avoid dehydration Once event resolves to ≤ Grade 1 or baseline, start loperamide 4 mg with each subsequent NERLYNX administration.
<ul style="list-style-type: none"> Any grade with complicated features† Grade 2 diarrhea lasting 5 days or longer‡ 	<ul style="list-style-type: none"> Interrupt NERLYNX treatment Diet modifications Fluid intake of ~2 L should be maintained to avoid dehydration

Severity of Diarrhea *	Action
<ul style="list-style-type: none"> Grade 3 diarrhea lasting longer than 2 days[‡] 	<ul style="list-style-type: none"> If diarrhea resolves to Grade 0-1 in one week or less, then resume NERLYNX treatment at the same dose. If diarrhea resolves to Grade 0-1 in longer than one week, then resume NERLYNX treatment at reduced dose (see Table 3). Once event resolves to ≤ Grade 1 or baseline, start loperamide 4 mg with each subsequent NERLYNX administration.
<ul style="list-style-type: none"> Grade 4 diarrhea [life-threatening consequences; urgent intervention indicated] Diarrhea recurs to Grade 2 or higher at 120 mg per day 	<ul style="list-style-type: none"> Permanently discontinue NERLYNX treatment

* Per CTCAE v4.0

† Complicated features include dehydration, fever, hypotension, renal failure, or Grade 3 or 4 neutropenia

‡ Despite being treated with optimal medical therapy

Table 7. NERLYNX in Combination with Capecitabine Dose Modifications for Diarrhea

Severity of Diarrhea *	Action
<ul style="list-style-type: none"> Grade 1 diarrhea [increase of < 4 stools per day over baseline] Grade 2 diarrhea [increase of 4-6 stools per day over baseline] lasting ≤ 5 days Grade 3 diarrhea [increase of ≥ 7 stools per day over baseline; incontinence; hospitalization indicated; limiting self-care activities of daily living] lasting ≤ 2 days 	<ul style="list-style-type: none"> Adjust antidiarrheal treatment Continue NERLYNX and capecitabine at full doses Fluid intake of ~2 L/day should be maintained to avoid dehydration Once event resolves to ≤ Grade 1 or baseline, start loperamide 4 mg with each subsequent NERLYNX administration.
<ul style="list-style-type: none"> Persisting and intolerable Grade 2 Diarrhea: lasting > 5 days Grade 3 Diarrhea lasting > 2 days Grade 4 Diarrhea [life-threatening consequences; urgent intervention indicated] 	<ul style="list-style-type: none"> Adjust antidiarrheal treatment Hold NERLYNX and capecitabine until recovery to Grade ≤ 1 or baseline Diet modifications Fluid intake of ~ 2 L/day should be maintained intravenously, if needed If recovery occurs: <ul style="list-style-type: none"> ≤ 1 week after withholding treatment, resume same doses of NERLYNX and capecitabine

Severity of Diarrhea *	Action
	<ul style="list-style-type: none"> ▪ Within 1 – 3 weeks after withholding treatment, reduce NERLYNX dose to 160 mg and maintain the same dose of capecitabine • If event occurs a second time and the NERLYNX dose has not already been decreased, reduce NERLYNX dose to 160 mg (maintain the same dose of capecitabine). If NERLYNX dose has already been reduced, then reduce the dose of capecitabine to 550 mg/m² given twice daily^a (maintain the same dose of NERLYNX). • If subsequent events occur, reduce the dose of NERLYNX or capecitabine to the next lower dose level in an alternate fashion (i.e. reduce capecitabine to 375 mg/m² given twice daily^a if NERLYNX was previously reduced, or reduce NERLYNX to 120 mg if capecitabine was previously reduced). • Once the event resolves to Grade ≤ 1 or baseline, start loperamide 4 mg with each subsequent NERLYNX administration.

Abbreviations: L: liter

*NCI CTCAE v.4.0

^a Since capecitabine is provided as 150 mg or 500 mg tablets, it is recommended that the capecitabine dose reduction(s) is rounded down to the nearest 500 mg or multiple of 150 mg for the twice daily dose. If the patient's body surface area is >2.0, the standard of care for the study center can be utilized for capecitabine mg/m² dosing.

Dose Modifications for Hepatotoxicity

Guidelines for dose adjustment of NERLYNX in the event of liver toxicity are shown in Table 8. Patients who experience ≥ Grade 3 diarrhea, requiring IV fluid treatment, or any signs or symptoms of hepatotoxicity, such as worsening of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash or eosinophilia should be evaluated for changes in liver function tests. Fractionated bilirubin and prothrombin time should also be collected during hepatotoxicity evaluation (see 7 WARNINGS AND PRECAUTIONS).

Table 8. Dose Modification for Hepatotoxicity

Severity of Hepatotoxicity*	Action
<ul style="list-style-type: none"> • Grade 3 ALT or AST (>5-20x ULN) OR • Grade 3 bilirubin (>3-10x ULN) 	<ul style="list-style-type: none"> • Hold NERLYNX until recovery to ≤ Grade 1 • Resume NERLYNX at the next lower dose level if recovery to ≤ Grade 1 occurs within 3 weeks. If Grade 3 ALT, AST or bilirubin occurs again despite one dose reduction, permanently discontinue NERLYNX
<ul style="list-style-type: none"> • Grade 4 ALT or AST (>20x ULN) 	<ul style="list-style-type: none"> • Permanently discontinue NERLYNX

Severity of Hepatotoxicity*	Action
OR • Grade 4 bilirubin (>10x ULN)	
Signs or symptoms related to liver injury with either: • Grade 2 ALT or AST (>2.5-5x ULN) OR • Grade 2 bilirubin (>1.5-3x ULN)	
ALT or AST >3x ULN and bilirubin >2x ULN and alkaline phosphatase <2x ULN (potentially Hy's Law indicators of drug-induced liver damage)	

ULN = Upper Limit Normal; ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase

* Per CTCAE v4.0

Dose Modifications for Renal Impairment

No dose adjustment is necessary in patients with mild to moderate renal impairment. NERLYNX has not been studied in patients with severe renal impairment (10 CLINICAL PHARMACOLOGY, 10.3 Pharmacokinetics, Special Populations and Conditions).

Dose Modifications for Hepatic Impairment

No dose modifications are recommended for patients with mild to moderate hepatic impairment (Child-Pugh A or B) (see 7 WARNINGS AND PRECAUTIONS, Hepatotoxicity and 10 CLINICAL PHARMACOLOGY. Reduce the NERLYNX starting dose to 80 mg in patients with severe hepatic impairment (Child-Pugh C).

Pediatrics (< 18 years old)

Health Canada has not authorized an indication for pediatric use.

Geriatrics (≥ 65 years old)

No dose adjustment of NERLYNX is required in patients of ≥ 65 years of age. Older patients may experience higher toxicity and/or lower tolerance to NERLYNX treatment (see 7 WARNINGS and PRECAUTIONS).

4.4 Administration

NERLYNX tablets should be swallowed whole with a glass of water (tablets should not be chewed, crushed or split prior to swallowing). High-fat meal may lead to higher exposures of NERLYNX than a standard breakfast (see 9 DRUG INTERACTIONS, 9.5 Drug-Food Interactions).

4.5 Missed Dose

If a patient misses a dose, do not replace missed dose, and instruct the patient to resume

NERLYNX with the next scheduled daily dose.

5 OVERDOSAGE

There is no specific antidote, and the benefit of hemodialysis in the treatment of NERLYNX overdose is unknown. In the event of an overdose, administration of NERLYNX should be withheld and general supportive measures undertaken.

In the clinical trial setting, a limited number of patients reported overdose. The adverse reactions experienced by these patients were diarrhea, nausea, vomiting, and dehydration. The frequency and severity of gastrointestinal disorders (diarrhea, abdominal pain, nausea and vomiting) appear to be dose related.

For management of a suspected drug overdose, contact your regional poison control centre.

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table 9. Dosage Forms, Strengths, Composition and Packaging

Route of Administration	Dosage Form / Strength / Composition	Non-medicinal Ingredients
Oral	Tablet, 40 mg neratinib (equivalent to 48.3 mg neratinib maleate). NERLYNX tablets are supplied as red, oval shaped and debossed, film-coated 40 mg tablets with 'W104' on one side and plain on the other side.	Tablet core: colloidal silicon dioxide, crospovidone, magnesium stearate, mannitol, microcrystalline cellulose, povidone, and purified water. Film coating: iron oxide red, polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide.

Packaging

NERLYNX is available in white, opaque round HDPE bottles, containing 180 tablets, with a child-resistant closure and foil-lined induction seal. An HDPE desiccant canister with 1 g silica gel is enclosed with the drug product in each container.

7 WARNINGS AND PRECAUTIONS

Cardiovascular

Decreased Left Ventricular Function

In both extended adjuvant (ExteNET trial) and metastatic (NALA) settings, patients with left ventricular ejection fraction (LVEF) either below institutional lower limit of normal or below 50%, symptomatic congestive heart failure of NYHA class 2 or higher, QTcF > 450 msec, ventricular arrhythmia requiring medical therapy, or with a history of myocardial infarction within 12 months were excluded from the study.

In the randomized, placebo-controlled study (ExteNET trial) conducted in the extended adjuvant setting, Grade 3 ejection fraction decrease or congestive cardiac failure was reported in 5 (0.4%) patients in the NERLYNX arm and 2 (0.1%) patients in the placebo arm. In the NERLYNX arm, 15 (1.1%) patients discontinued treatment due to decreased ejection fraction or left ventricular dysfunction versus 6 (0.4%) patients in the placebo arm.

In the randomized, active-controlled study (NALA trial) conducted in the metastatic setting, Grade 3 ejection fraction decrease or congestive cardiac failure was reported in 1 (0.3%) patient in the NERLYNX arm. In the NERLYNX arm, 1 (0.3%) patient discontinued treatment due to decreased ejection fraction.

In patients with known cardiac risk factors, conduct cardiac monitoring, including assessment of LVEF, as clinically indicated.

Gastrointestinal

Diarrhea

Severe diarrhea and sequelae, such as dehydration, hypotension, and renal failure, have been reported during treatment with NERLYNX.

In the randomized, placebo-controlled study (ExteNET trial) conducted in the extended adjuvant setting, diarrhea of any grade occurred in 95% of NERLYNX-treated patients, Grade 3 diarrhea occurred in 40%, and Grade 4 diarrhea occurred in 0.1% of NERLYNX-treated patients (see 8 ADVERSE REACTIONS). The majority of patients (93%) had diarrhea in the first month of treatment, with a median time to the first onset of Grade \geq 3 diarrhea of 8 days (range: 1-350 days). The median cumulative duration of Grade \geq 3 diarrhea was 5 days (range: 1-139 days). NERLYNX treatment was discontinued in 17% of patients due to diarrhea.

In the randomized, active-controlled study (NALA trial) conducted in the metastatic setting, diarrhea was reported in 83% of NERLYNX plus capecitabine treated patients who were required to receive anti-diarrheal prophylaxis in the first cycle. The majority of patients (70%) had diarrhea in the first cycle of treatment, the median time to first onset of Grade \geq 3 diarrhea was 11 days (range: 2-728) and the median cumulative duration of Grade \geq 3 diarrhea was 4 days (range: 1-24). In the NERLYNX plus capecitabine arm, Grade 3 diarrhea occurred in 25% of patients, and NERLYNX treatment was discontinued in 2.3% of patients due to diarrhea (see 8 ADVERSE REACTIONS).

Either a two-week NERLYNX dose escalation (with loperamide taken as needed) or antidiarrheal prophylaxis with loperamide for the first 56 days of treatment, is recommended to lower the incidence and severity of diarrhea (see 4 DOSAGE AND ADMINISTRATION and 8 ADVERSE REACTIONS). In addition, proactively manage diarrhea at the first unformed stool, especially within the first 2 weeks of starting NERLYNX. Measures include adequate oral hydration, avoiding foods that might aggravate diarrhea, and treatment with additional antidiarrheal therapy as needed.

When severe diarrhea with dehydration occurs, administer fluid and electrolytes as needed, interrupt NERLYNX and reduce subsequent doses. Permanently discontinue NERLYNX in patients with diarrhea recurring to Grade \geq 2 at 120 mg NERLYNX daily dose or with Grade 4 diarrhea (see 4 DOSAGE AND ADMINISTRATION). Perform stool cultures as clinically

indicated to exclude infectious causes of Grade 3 or 4 diarrhea or diarrhea of any grade with complicating features (dehydration, fever, neutropenia).

Hepatic / Biliary / Pancreatic

Hepatotoxicity

NERLYNX has been associated with hepatotoxicity, characterized by increased liver enzymes.

In the randomized, placebo-controlled study (ExteNET trial) conducted in the extended adjuvant setting, 12% of patients treated with NERLYNX reported hepatotoxicity, including 5% of patients who experienced an alanine aminotransferase (ALT) increase or an aspartate aminotransferase (AST) increase $\geq 3x$ ULN (\geq Grade 2). Of those, 1.7% of patients experienced an AST or ALT elevation $> 5x$ ULN (\geq Grade 3). Increased bilirubin was reported in 1% of patients. Hepatotoxicity or increases in liver transaminases led to drug discontinuation in 1.7% of NERLYNX-treated patients. The median time of onset to any hepatotoxicity was 31 (range: 1 - 358) days.

In the randomized, active-controlled study (NALA trial) conducted in the metastatic setting, 7% of patients treated with NERLYNX and capecitabine experienced an ALT or AST $> 3x$ ULN, 2% experienced ALT or AST $> 5x$ ULN, 7% experienced bilirubin $> 1.5x$ ULN, and 1.3% experienced bilirubin $> 3x$ ULN. Hepatotoxicity or increases in liver transaminases led to drug discontinuation in 0.3% of NERLYNX and capecitabine-treated patients. The median time of onset to any hepatotoxicity was 57 (range: 2-1071) days.

Liver function tests should be conducted prior to and during NERLYNX treatment (see Monitoring and Laboratory Tests below). Dose modifications are recommended for patients with treatment-emergent hepatotoxicity. NERLYNX treatment should be permanently discontinued in patients with Grade 4 increases in liver transaminases ($> 20x$ ULN), Grade 4 bilirubin ($> 10x$ ULN), or in those with ALT/AST $\geq 3x$ ULN and bilirubin $> 2x$ ULN (see 4 DOSAGE AND ADMINISTRATION).

Monitoring and Laboratory Tests

Liver Function Monitoring

Liver function tests including total bilirubin, ALT, AST, and alkaline phosphatase should be measured prior to starting treatment with NERLYNX and monthly for the first 3 months of treatment, then every 3 months while on treatment and as clinically indicated. These tests should also be performed in patients experiencing Grade 3 diarrhea or any signs or symptoms of hepatotoxicity, such as worsening of fatigue, nausea, vomiting, right upper quadrant tenderness, fever, rash, or eosinophilia. Fractionated bilirubin and prothrombin time should also be collected during hepatotoxicity evaluation (see 4 DOSAGE AND ADMINISTRATION, Dose Modifications for Hepatotoxicity and 8 ADVERSE REACTIONS).

Left Ventricular Function Testing

In patients with known cardiac risk factors, conduct cardiac monitoring, including assessment of LVEF, as clinically indicated.

Reproductive Health: Female and Male Potential

- **Fertility**

Fertility studies in humans have not been performed with NERLYNX. In a fertility study in rats, neratinib caused no effects on mating or the ability of animals to become pregnant; however, effects on male reproductive organs were observed in chronic, repeated-dose toxicity studies (see 16 NON-CLINICAL TOXICOLOGY).

- **Teratogenic Risk**

Women of childbearing potential must be advised to avoid pregnancy while on NERLYNX. Female patients of child-bearing potential must use highly effective contraceptive methods during treatment and for at least 1 month after the last dose (see 16 NON-CLINICAL TOXICOLOGY). Pregnancy testing is recommended for women of reproductive potential prior to starting treatment with NERLYNX.

Men with female partners of reproductive potential should be advised to use effective contraception during treatment with NERLYNX and for 3 months after the final dose.

7.1 Special Populations

7.1.1 Pregnant Women

There are no data regarding the use of NERLYNX in pregnant women. In animal studies, administration of neratinib to pregnant rabbits during organogenesis caused abortions, embryo-fetal death and fetal abnormalities at maternal exposures approximately 0.2 times the exposure in patients receiving the recommended dose (see 16 NON-CLINICAL TOXICOLOGY). Based on its mechanism of action and findings from nonclinical reproduction studies, NERLYNX can cause fetal harm when administered to a pregnant woman.

NERLYNX is not recommended during pregnancy and in women of childbearing potential not using effective contraception. If the patient becomes pregnant while taking NERLYNX, the patient should be informed of the potential hazard to the fetus.

7.1.2 Breast-feeding

It is unknown if neratinib or its metabolites are excreted in human milk. As many drugs are excreted in human milk, and because of the potential for serious adverse reactions in breastfed infants from NERLYNX, advise lactating women not to breastfeed while taking NERLYNX and for at least 1 month after the last dose (see 16 NON-CLINICAL TOXICOLOGY).

7.1.3 Pediatrics

Pediatrics (<18 years): No data are available to Health Canada, therefore Health Canada has not authorized an indication for pediatric use.

7.1.4 Geriatrics

In the ExteNET trial, which was conducted in the extended adjuvant setting, the mean age was 52 years in the NERLYNX arm; 12% were \geq 65 years including 2% who were 75 years or older.

In the NERLYNX arm, a greater percentage of older patients (45%) compared with younger patients (25%) experienced treatment discontinuation due to adverse reactions. Diarrhea was the most common adverse reaction leading to treatment discontinuation, which was reported in 29% of older patients and 15% of younger patients.

The incidence of serious adverse reactions in the NERLYNX arm was 7.0% in the < 65 years-old group and 9.9% in the ≥ 65 years-old group. The serious adverse reactions most frequently reported in the ≥ 65 years-old group were vomiting (2.3%), diarrhea (1.7%), renal failure (1.7%), and dehydration (1.2%).

In the NALA trial, which was conducted in the metastatic setting, the mean age was 55 years in the NERLYNX plus capecitabine arm; 63 (21%) patients were ≥ 65 years, of whom 12 (4%) patients were 75 years or older.

In the NERLYNX plus capecitabine arm, a similar percentage of older patients ≥ 65 years (12%) compared with younger patients < 65 years (15%) experienced treatment discontinuation due to adverse reactions. Diarrhea was the most common adverse reaction leading to treatment discontinuation, which was reported in 3% of patients of all ages.

The incidence of serious adverse reactions in the NERLYNX plus capecitabine arm in the ≥ 65 years-old group was 36% and in the < 65 years-old group was 34%. The serious adverse reactions most frequently reported in the ≥ 65 years-old group were diarrhea (16%), acute kidney injury (8%), and dehydration (7%).

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

Extended Adjuvant Treatment of Early-Stage Breast Cancer

In the randomized, double blind, placebo-controlled study (ExteNET) in women with HER2-positive early-stage breast cancer after completion of trastuzumab-based adjuvant therapy, patients were treated with NERLYNX or placebo for one year. The median duration of treatment was similar between the two arms: 11.6 (range: 0.03-13.3) months in the NERLYNX arm and 11.8 (range: 0.13-13.2) months in the placebo arm.

Patients treated with NERLYNX experienced higher incidences of treatment-emergent adverse events (99% vs 88%), grade 3-4 adverse events (50% vs 13%), and treatment-related adverse events (96% vs 57%) than those treated with placebo.

In the NERLYNX arm, the most common adverse reactions (≥ 10%) were diarrhea (95%), nausea (43%), abdominal pain (36%), fatigue (27%), vomiting (26%), rash (18%), stomatitis (14%), decreased appetite (12%), muscle spasms (11%), and dyspepsia (10%) (Table 10).

Serious adverse reactions were reported in 7% of patients treated with NERLYNX and 6% of patients treated with placebo. Serious adverse reactions reported in ≥ 3 patients in the NERLYNX arm included diarrhea (1.6%), vomiting (0.9%), dehydration (0.6%), cellulitis (0.4%), renal failure (0.4%), erysipelas (0.4%), alanine aminotransferase increased (0.3%), aspartate aminotransferase increased (0.3%), nausea (0.3%), fatigue (0.2%), and abdominal pain (0.2%).

NERLYNX dose reduction and dose interruption due to an adverse reaction occurred in 31.2% and 45% of patients, respectively. Permanent discontinuation due to any adverse reaction was reported in 27.6% of NERLYNX-treated patients. The most common adverse reaction leading to discontinuation was diarrhea, accounting for 16.8% of NERLYNX-treated patients.

Metastatic Breast Cancer

The randomized, multi-center, multinational, open-label, active-controlled study (NALA) was conducted in patients with HER2-positive metastatic breast cancer, who have received two or more prior anti-HER2-based regimens in the metastatic setting (see 14 CLINICAL TRIALS). The median duration of treatment was 5.7 months in the NERLYNX plus capecitabine arm and 4.4 months in the lapatinib plus capecitabine arm.

Similar proportions of patients treated with NERLYNX plus capecitabine and patients treated with lapatinib plus capecitabine experienced treatment-emergent adverse events (100% vs 99%), grade 3-4 adverse events (61% vs 60%), fatal adverse events (2.6% vs 3.2%), and treatment-related adverse events (95% vs 96%).

In the NERLYNX plus capecitabine arm, the most common adverse reactions ($\geq 10\%$) were diarrhea (83%), nausea (53%), palmar-plantar erythrodysesthesia syndrome (46%), vomiting (46%), fatigue/asthenia (45%), decreased appetite (35%), constipation (31%), stomatitis (28%), weight decreased (20%), rash (18%), nail disorders (15%), dizziness (14%), back pain (10%) and arthralgia (10%) (Table 11).

Serious adverse reactions were reported in 34% of patients treated with NERLYNX plus capecitabine and 30% of patients treated with lapatinib plus capecitabine. Serious adverse reactions reported in ≥ 3 patients (1%) in the NERLYNX plus capecitabine arm included diarrhea (7.3%), pleural effusion (3.3%), vomiting (3.0%), acute kidney injury (2.3%), nausea (2.3%), metastases to central nervous system (2.0%), pneumonia (2.0%), cellulitis (1.3%), dehydration (1.3%), seizure (1.3%), constipation (1.0%), pyrexia (1.0%), and urinary tract infection (1.0%).

Adverse reactions leading to dose hold of any study drugs were reported in 64% of patients treated with NERLYNX plus capecitabine and in 64% of patients treated with lapatinib plus capecitabine. NERLYNX and lapatinib dose hold due to an adverse reaction occurred in 50% and 47% of patients receiving NERLYNX plus capecitabine and lapatinib plus capecitabine, respectively.

Adverse reactions leading to dose reduction of any study drugs were reported in 24% of patients treated with NERLYNX plus capecitabine and in 30% of patients treated with lapatinib plus capecitabine. NERLYNX and lapatinib dose reduction due to an adverse reaction occurred in 10% and 11% of patients receiving NERLYNX plus capecitabine and lapatinib plus capecitabine, respectively.

Adverse reactions leading to discontinuation of any study drugs occurred in 14% of patients treated with NERLYNX plus capecitabine and in 18% of patients treated with lapatinib plus capecitabine. Discontinuation of NERLYNX and lapatinib due to an adverse reaction was reported in 11% and 15% of patients treated with NERLYNX plus capecitabine and lapatinib plus capecitabine, respectively. The most common adverse reactions leading to discontinuation of NERLYNX were vomiting (3.3%), diarrhea (2.3%), nausea (1.7%), and pleural effusion (1.0%).

8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

ExteNET

Table 10 summarizes the incidence rates of adverse drug reactions occurring at $\geq 2\%$ of patients and with higher incidences reported in the NERLYNX arm in the ExteNET trial. Patients who received NERLYNX in this trial were not required to receive any prophylaxis with antidiarrheal agents to prevent the NERLYNX-related diarrhea.

Table 10. Incidence Rate of Adverse Reactions Reported in $\geq 2\%$ of Patients treated with NERLYNX and with Higher Incidence Rates in the NERLYNX arm in ExteNET Study

System Organ Class (Preferred Term)	NERLYNX n = 1408			Placebo n = 1408		
	All Grades (%)	Grade 3 (%)	Grade 4 (%)	All Grades (%)	Grade 3 (%)	Grade 4 (%)
Gastrointestinal Disorders						
Diarrhea	95	40	0.1	35	2	0
Nausea	43	2	0	22	0.1	0
Abdominal pain*	36	2	0	15	0.4	0
Vomiting	26	3	0	8	0.4	0
Stomatitis†	14	0.6	0	6	0.1	0
Dyspepsia	10	0.4	0	4	0	0
Abdominal distension	5	0.3	0	3	0	0
Flatulence	5	0.1	0	3	0.1	0
Dry mouth	3	0.1	0	2	0	0
Hemorrhoids	2	0	0	1	0	0
General Disorders and Administration Site Conditions						
Fatigue	27	2	0	20	0.4	0
Pyrexia	6	0	0	4	0	0
Hepatobiliary Disorders						
Alanine aminotransferase increased	9	1	0.2	3	0.2	0
Aspartate aminotransferase increased	7	0.5	0.2	3	0.3	0
Infections and Infestations						
Urinary tract infection	5	0.1	0	2	0	0
Cystitis	3	0	0	1	0	0

System Organ Class (Preferred Term)	NERLYNX n = 1408			Placebo n = 1408		
	All Grades (%)	Grade 3 (%)	Grade 4 (%)	All Grades (%)	Grade 3 (%)	Grade 4 (%)
Investigations						
Weight decreased	5	0.1	0	0.5	0	0
Metabolism and Nutrition Disorders						
Decreased appetite	12	0.2	0	3	0	0
Dehydration	4	0.9	0.1	0.4	0.1	0
Musculoskeletal and Connective Tissue Disorders						
Muscle spasms	11	0.1	0	3	0.1	0
Respiratory, Thoracic and Mediastinal Disorders						
Epistaxis	5	0	0	1	0.1	0
Skin and Subcutaneous Tissue Disorders						
Rash [‡]	21	0.6	0	10	0.1	0
Dry skin	6	0	0	2	0	0
Nail Disorder [§]	8	0.3	0	2	0	0
Skin fissures	2	0.1	0	0.1	0	0

* Includes abdominal pain, abdominal pain upper, and abdominal pain lower

† Includes stomatitis, aphthous stomatitis, mouth ulceration, oral mucosal blistering, mucosal inflammation, oropharyngeal pain, oral pain, glossodynia, glossitis, and cheilitis

‡ Includes rash, rash erythematous, rash follicular, rash generalized, rash pruritic, rash pustular, rash maculo-papular, rash papular, dermatitis, dermatitis acneiform, toxic skin eruption, erythema multiforme, exfoliative rash, and acne

§ Includes nail disorder, paronychia, onychoclasia, nail discoloration, nail toxicity, nail growth abnormal, and nail dystrophy

NALA

Table 11 summarizes the incidence rates of adverse drug reactions occurring at $\geq 2\%$ of patients in the NERLYNX in combination with capecitabine arm in the NALA trial. Prophylactic therapy was implemented for enrolled patients in the NERLYNX plus capecitabine arm.

Table 11. Incidence Rate of Adverse Reactions Reported in $\geq 2\%$ of Patients treated with NERLYNX in combination with capecitabine in the NALA Study

System Organ Class (Preferred Term)	NERLYNX plus capecitabine n = 303			Lapatinib plus capecitabine n = 311		
	All Grades (%)	Grade 3 (%)	Grade 4 (%)	All Grades (%)	Grade 3 (%)	Grade 4 (%)
Gastrointestinal Disorders						
Diarrhea	83	25	0	66	13	0
Nausea	53	4.3	0	42	2.9	0
Vomiting	46	4	0	31	1.9	0
Constipation	31	1	0	13	0	0
Stomatitis [†]	28	2.3	0	33	2.6	0
Abdominal distension	8	0.3	0	3.2	0.6	0
General Disorders and Administration Site Conditions						
Fatigue/Asthenia	45	6	0	40	4.5	0
Malaise	4.3	0	0	2.3	0.3	0

System Organ Class (Preferred Term)	NERLYNX plus capecitabine n = 303			Lapatinib plus capecitabine n = 311		
	All Grades (%)	Grade 3 (%)	Grade 4 (%)	All Grades (%)	Grade 3 (%)	Grade 4 (%)
Influenza like illness	4	0	0	1.3	0	0
Infections and Infestations						
Urinary tract infection	9	0.7	0	4.2	0.6	0
Upper respiratory tract infection	8	0.3	0	4.5	0.3	0
Investigations						
Weight decreased	20	0.3	0	13	0.6	0
Metabolism and Nutrition Disorders						
Decreased appetite	35	2.6	0	22	2.3	0
Dehydration	5.9	2.3	0	6.4	1.9	0
Musculoskeletal and Connective Tissue Disorders						
Back Pain	10	0.3	0	8	0.3	0
Arthralgia	10	0	0	6	1	0
Muscle spasms	5	0	0	1.9	0	0
Nervous System Disorder						
Dizziness	14	0.3	0	10	0.6	0
Renal and Urinary Disorders						
Renal impairment*	7	2	0.3	1	0	0.3
Dysuria	4.6	0	0	1.9	0	0
Skin and Subcutaneous Tissues Disorders						
Palmar-plantar erythrodysesthesia syndrome	46	9.6	0	56	11	0
Rash‡	18	0.3	0	36	0.6	0
Nail Disorder§	15	0.7	0	21	1.0	0
Dry Skin	6.6	0	0	4.8	0	0
Skin Fissures	3	0	0	6.1	0.3	0

*Renal impairment includes acute kidney injury, blood creatinine increased, renal failure, and renal impairment.

†Stomatitis includes aphthous stomatitis, mouth ulceration, oral mucosal blistering, mucosal inflammation, oropharyngeal pain, oral pain, glossodynia, glossitis, and cheilitis

‡Rash includes rash erythematous, rash follicular, rash generalized, rash pruritic, rash pustular, rash maculo-papular, rash papular, dermatitis dermatitis acneiform, toxic skin eruption, erythema multiforme, exfoliative rash, and acne

§Nail disorder includes paronychia, onychoclasia, nail discoloration, nail toxicity, nail growth abnormal, and nail dystrophy

CONTROL (Prophylaxis Management of Diarrhea)

The CONTROL (NCT02400476) study was a multicenter, open-label, multi-cohort trial evaluating prophylaxis regimens in patients with early-stage HER2-positive breast cancer treated with neratinib 240 mg daily for up to one year. Patients in the loperamide cohort were given loperamide daily for 56 days and then as needed. Patients in the neratinib dose-escalation cohort were given 120 mg neratinib for week 1, followed by 160 mg neratinib for week 2, followed by 240 mg neratinib for week 3 and thereafter, with loperamide administered on an as-needed basis only. The median duration of treatment was 11.63 months for the loperamide cohort and 11.96 months for the dose-escalation cohort.

The primary endpoint for this study was the incidence of grade 3 diarrhea or higher. There were no events of either grade 4 or grade 5 diarrhea in any of the cohorts. The incidence of grade 3 diarrhea in the dose-escalation cohort was 13.3%, compared to 30.7% of patients who received loperamide. Compared to the ExteNet study (16.8%), the proportion of patients who had diarrhea leading to neratinib discontinuation was 3.3% in the dose-escalation cohort compared to 20.4% in the loperamide cohort. Dose-escalation was also associated with fewer other gastrointestinal adverse events such as constipation, abdominal pain, nausea, and vomiting.

Dose escalation was not evaluated in patients receiving neratinib in combination with capecitabine for the treatment of metastatic breast cancer.

8.3 Less Common Clinical Trial Adverse Reactions

ExteNET

The following treatment emergent adverse reactions were reported in less than 2% of patients and with higher incidences in the NERLYNX arm in the ExteNET study.

Gastrointestinal Disorders: gastroesophageal reflux disease (1.8%), gastritis (1.4%), gastrointestinal pain (1.1%).

General Disorders and Administration Site Conditions: chills (1.8%), malaise (1.8%),

Hepatobiliary Disorders: blood alkaline phosphatase increased (2%), hyperbilirubinemia (0.7%), cholelithiasis (0.5%).

Infections and Infestations: cellulitis (1.7%).

Renal and Urinary Disorders: dysuria (1.8%), renal failure and renal failure acute (0.6%), blood creatinine increased (1.0%).

Respiratory, thoracic and mediastinal disorders: rhinorrhoea (1.4%), nasal dryness (1.4%).

Skin and Subcutaneous Tissue Disorders: palmar-plantar erythrodysesthesia syndrome (1.8%), skin disorder (1%).

NALA

The following treatment emergent adverse reactions were reported in less than 2% of patients and with higher incidences in the NERLYNX in combination with capecitabine arm in the NALA study.

Gastrointestinal Disorders: pancreatitis (0.7%)

Investigations: amylase increased (1.7%)

8.4 Abnormal Laboratory Findings: Hematological, Clinical, Chemistry and Other Quantitative Data

Clinical Trial Findings

Table 12: Laboratory Abnormalities Reported in $\geq 10\%$ of Patients Treated with NERLYNX in ExteNET Study*

Laboratory Tests	NERLYNX n = 1408			Placebo n = 1408		
	All Grades (%)	Grade 3 (%)	Grade 4 (%)	All Grades (%)	Grade 3 (%)	Grade 4 (%)
Chemistry						
Alanine Aminotransferase increased	35	2	0.2	23	0.4	0.1
Alkaline Phosphatase increased	21	0	0	24	0.1	0
Aspartate Aminotransferase increased	26	0.8	0.1	18	0.4	0.1
Bilirubin increased	10	0.1	0.0	11	0.4	0.1
Creatinine increased	11	0.1	0.1	8	0	0
Hematology						
Hemoglobin decreased	35	0.2	0.4	23	0	0.4

* Grades using NCI CTCAE version 3.0.

Table 13: Laboratory Abnormalities Reported in $\geq 10\%$ of Patients Treated with NERLYNX in Combination with Capecitabine in NALA Study*

Laboratory Tests	NERLYNX plus capecitabine n = 303			Lapatinib plus capecitabine n = 311		
	All Grades (%)	Grade 3 (%)	Grade 4 (%)	All Grades (%)	Grade 3 (%)	Grade 4 (%)
Chemistry						
Alanine Aminotransferase increased	24	0.7	0	23	1.3	0
Alkaline Phosphatase increased	16	0.3	0	23	1.3	0
Aspartate Aminotransferase increased	29	1	0	31	2.3	0

Laboratory Tests	NERLYNX plus capecitabine n = 303			Lapatinib plus capecitabine n = 311		
	All Grades (%)	Grade 3 (%)	Grade 4 (%)	All Grades (%)	Grade 3 (%)	Grade 4 (%)
Bilirubin increased	20	1	0.3	43	5.1	0.3
Creatinine increased	15	0	0	11	0	0
Hematology						
Hemoglobin decreased	48	2	0	35	3	0

* Grades using NCI CTCAE version 3.0.

9 DRUG INTERACTIONS

9.2 Drug Interactions Overview

Neratinib is primarily metabolized in the liver by CYP3A4. It is also a substrate of P-glycoprotein (P-gp). Drug interactions were observed when NERLYNX was coadministered with a strong CYP3A4/P-gp inhibitor and a strong CYP3A4/P-gp inducer. Simulated concomitant use of NERLYNX with a moderate CYP3A4/P-gp inhibitor or a moderate CYP3A4 inducer suggests significant changes in neratinib plasma concentrations. The relative contributions of CYP3A4 and P-gp to the pharmacokinetics of neratinib are unknown. The solubility of neratinib maleate increases dramatically as neratinib becomes protonated at acidic pH. Drug interactions were observed when NERLYNX was coadministered with a proton pump inhibitor (PPI) and a H₂-receptor antagonist under fed conditions.

Neratinib may inhibit the transport of P-gp substrate and increase the exposure of co-administered medicinal products primarily cleared by P-gp.

9.4 Drug-Drug Interactions

The drugs listed in Table 14 are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction.

Table 14. Established or Potential Drug-Drug Interactions

Common name	Source of Evidence	Effect	Clinical comment
Pharmacokinetic Interactions (Drugs that may affect the exposure to neratinib)			
Strong inhibitor of CYP3A4/P-gp (e.g., boceprevir, clarithromycin, cobicistat, conivaptan, diltiazem, idelalisib, indinavir, itraconazole, ketoconazole, lopinavir, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, tipranavir, troleandomycin, voriconazole)	CT	Concomitant use of NERLYNX with a strong CYP3A4/P-gp inhibitor (ketoconazole) increased neratinib C _{max} by 321% and AUC by 481%.	Avoid concomitant use of NERLYNX with strong CYP3A4 and/or P-gp inhibitors.
Moderate inhibitor of CYP3A4/P-gp (e.g., aprepitant, cimetidine, ciprofloxacin, clotrimazole, crizotinib, cyclosporine, diltiazem, dronedarone, erythromycin, fluconazole, fluvoxamine, imatinib, tofisopam, verapamil)	T	<p>Simulated concomitant use of NERLYNX with a moderate CYP3A4 inhibitor (fluconazole) suggests that neratinib C_{max} and AUC may increase by 30% and 68%, respectively.</p> <p>Simulated concomitant use of NERLYNX with a moderate CYP3A4/P-gp inhibitor (verapamil) suggests the neratinib C_{max} and AUC may increase by 203% and 299%, respectively.</p> <p>Concomitant use of NERLYNX with other moderate CYP3A4/P-gp inhibitors may increase neratinib concentrations.</p> <p>Increased neratinib concentrations may increase the risk of toxicity.</p>	Avoid concomitant use of NERLYNX with moderate CYP3A4 and/or P-gp inhibitors.

Strong inducer of CYP3A4/P-gp (e.g., carbamazepine, enzalutamide, mitotane, phenytoin, rifampin)	CT	Concomitant use of NERLYNX with a strong CYP3A4/P-gp inducer (rifampin) reduced neratinib C_{max} by 76% and AUC by 87%.	Avoid concomitant use of NERLYNX with strong CYP3A4 and/or P-gp inducers.
Moderate inducer of CYP3A4 (e.g., efavirenz)	T	Simulated concomitant use of NERLYNX with moderate CYP3A4 inducer (efavirenz) suggests the decrease the C_{max} and AUC of neratinib by 36% and 52%, respectively.	Avoid concomitant use of NERLYNX with moderate CYP3A4 and/or P-gp inducers.
Antacids	T	Drugs that alter the pH of the upper GI tract, may alter the solubility of neratinib and hence its bioavailability.	Separate dosing of NERLYNX and antacids by 3 hours.
Proton Pump Inhibitor	CT	In a trial of 15 healthy subjects, administration of a single 240 mg dose of NERLYNX combined with a 30 mg lansoprazole dose at steady state decreased neratinib C_{max} and AUC by 71% and 65%, respectively.	Avoid concomitant use.
H ₂ -receptor antagonist	CT	When NERLYNX was administered 2 hours following a 300 mg dose of an H ₂ -receptor antagonist (ranitidine), the neratinib C_{max} and AUC were reduced by 55% and 47%, respectively. When NERLYNX was administered 2 hours prior to ranitidine 150 mg twice daily (administered in the morning and evening, approximately 12 hours apart), the neratinib C_{max} and AUC were reduced by 40% and 30%, respectively.	Avoid concomitant use. If short-term use of a H ₂ -receptor antagonist cannot be avoided, NERLYNX must be taken at least 2 hours before the morning dose and 10 hours after the evening dose of the H ₂ -receptor antagonist dosing.

Pharmacokinetic Interactions (Drugs that may have their plasma concentrations altered by NERLYNX)			
P-glycoprotein substrate (e.g., digoxin, dabigatran, fexofenadine)	CT	Concomitant use of digoxin (a single 0.5 mg oral dose), a P-gp substrate, with multiple oral doses of NERLYNX 240 mg in healthy subjects (n=18) increased the mean digoxin C _{max} by 54% and AUC by 32%.	Caution is warranted and therapeutic concentration monitoring of P-gp substrates with a narrow therapeutic index is recommended.

Legend: C = Case Study; CT = Clinical Trial; T = Theoretical

9.5 Drug-Food Interactions

Grapefruit, grapefruit juice, and products containing grapefruit extract may increase neratinib plasma concentrations and should be avoided.

The food-effect assessment was conducted in healthy volunteers who received NERLYNX 240 mg under fasting conditions and with high-fat food (approximately 55% fat, 31% carbohydrate, and 14% protein) or standard breakfast (approximately 50% carbohydrate, 35% fat, and 15% protein). A high-fat meal increased neratinib C_{max} and AUC_{inf} by 1.7-fold (90% CI: 1.1- 2.7) and 2.2-fold (90% CI: 1.4- 3.5), respectively. A standard breakfast increased the C_{max} and AUC_{inf} by 1.2-fold (90% CI: 0.97- 1.42) and 1.1-fold (90% CI: 1.02- 1.24), respectively.

9.6 Drug-Herb Interactions

Interactions with herbal products have not been established. St. John's wort (*Hypericum perforatum*) is an inducer of CYP3A4 that may decrease neratinib plasma concentrations and should be avoided.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

Neratinib is a protein kinase inhibitor that irreversibly binds to Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and HER4. *In vitro*, neratinib reduces EGFR and HER2 autophosphorylation, downstream MAPK and AKT signaling pathways, and showed antitumor activity in EGFR and/or HER2 expressing carcinoma cell lines. Neratinib human metabolites M3, M6, M7 and M11 inhibited the activity of EGFR, HER2 and HER4 *in vitro*. *In vivo*, oral administration of neratinib inhibited tumor growth in mouse xenograft models with tumor cell lines expressing HER2 and EGFR.

10.2 Pharmacodynamics

Cardiac Electrophysiology

The effects of NERLYNX on ECG interval parameters were evaluated in a randomized, placebo- and positive-controlled, double-blind, single-dose, crossover study in 60 healthy subjects. The study was conducted in two parts. Part A was a three-way crossover of single dose treatment with test article (neratinib 240 mg, placebo, or moxifloxacin 400 mg) in a fed state. Part B was a two-way crossover of a single dose of test article (neratinib 240 mg or

placebo) co-administered with ketoconazole 400 mg/day in a fasting state. Ketoconazole 400 mg was administered for four days, beginning one day prior to neratinib administration.

Following single dose treatment with neratinib 240 mg, in the presence and absence of the CYP3A inhibitor, ketoconazole 400 mg/day, no clinically relevant effects on the QTc interval, the QRS duration, the PR interval, or ventricular heart rate were observed. The mean (SD) C_{max} of single dose neratinib 240 mg was 68.0 (27.0) ng/mL when administered alone and 162.6 (75.0) ng/mL when administered with ketoconazole 400 mg/day.

10.3 Pharmacokinetics

Neratinib exhibits a non-linear PK profile with less than dose proportional increase of AUC with increasing daily dose over the range of 40 to 400 mg.

Table 15 summarizes the single dose PK parameters in healthy subjects under fed and fasted conditions.

Table 15. Summary of Pharmacokinetics (PK) Parameters of NERLYNX Following Single Ascending Oral Doses of 240 mg of NERLYNX to Healthy Subjects under Fasted and Fed Conditions: Arithmetic Mean (+SD).

		C _{max} (ng/mL)	T _{max} (hr)	t _{1/2} (h)	AUC _{0-∞} (ng.h/mL)	CL (L/hr/kg)	Vd (L/kg)
Single dose mean	Fed (high fat)	74.4 (20.87)	6	11 (1.84)	1357 (386)	2.62 (0.66)	40.8 (7.86)
	Fasted	44.6 (15.0)	4	9.8 (2.97)	667 (268)	6.27 (4.63)	78.6 (36.39)

C_{max} = maximum (peak) concentration; T_{max} = median time at peak concentration; T_{1/2} = half-life; AUC = total area under the time-concentration curve; CL/F = apparent clearance; Vd = apparent volume of distribution

Absorption: Following oral single-dose administration, neratinib showed a moderate rate of absorption with a median T_{max} after approximately 6 hours under fed conditions versus 4 hours under fasted conditions.

A preliminary food-effect assessment was conducted in healthy subjects who received NERLYNX 240 mg under fasting conditions and with high-fat food (approximately 55% fat, 31% carbohydrate, and 14% protein) or standard breakfast (approximately 50% carbohydrate, 35% fat, and 15% protein). A high-fat meal increased neratinib C_{max} and AUC_{inf} by 1.7-fold (90% CI: 1.1- 2.7) and 2.2-fold (90% CI: 1.4- 3.5), respectively. A standard breakfast increased the C_{max} and AUC_{inf} by 1.2-fold (90% CI: 0.97- 1.42) and 1.1-fold (90% CI: 1.02- 1.24), respectively.

Distribution: In patients, following multiple doses of NERLYNX, the mean (%CV) apparent volume of distribution at steady-state (V_{ss}/F) was 6433 (19%) L. *In vitro* protein binding of neratinib in human plasma was greater than 99% and independent of concentration. Neratinib was bound predominantly to human serum albumin and human alpha-1 acid glycoprotein.

Metabolism: Neratinib is metabolized primarily in the liver by CYP3A4 and to a lesser extent by flavin-containing monooxygenase (FMO).

Following oral administration of NERLYNX, neratinib represents the most prominent component in plasma. At steady state after 240 mg daily oral doses of NERLYNX in healthy subjects (N = 25), the systemic exposures (AUC) of the active metabolites M3, M6, M7 and M11 were 15%, 33%, 22% and 4% of the systemic neratinib exposure (AUC), respectively.

Elimination: The mean apparent oral clearance (CL/F) of neratinib was high and variable (ranging from 159 L/kg to 456 L/kg (2.0 to 6.3 L/h/kg)), relatively similar at all dosages, and similar in healthy volunteers and cancer patients. Following single doses of neratinib, the mean apparent plasma half-life of neratinib was 17 hours in patients.

In a mass balance analysis in healthy subjects, after oral administration of 200 mg NERLYNX, fecal excretion accounted for approximately 97.1% and urinary excretion accounted for 1.13% of the total dose. The excretion was rapid and complete with the majority of the radioactivity (61%) recovered within 96 hours and 98% recovered after 10 days.

Special Populations and Conditions

- **Pediatrics:** Pharmacokinetic studies of neratinib have not been evaluated in children under 18 years of age.
- **Geriatrics:** Age (range, 28-90 years of age) has no clinically significant effect on neratinib pharmacokinetics in patients with cancer based on a population PK analysis.
- **Gender:** Population pharmacokinetic analyses showed that sex had no clinically meaningful effect on the pharmacokinetics of neratinib.
- **Ethnic Origin:** Based on a population PK analysis, race does not have a clinically significant effect on neratinib pharmacokinetics.
- **Hepatic Insufficiency:** Neratinib is mainly metabolized in the liver. Single doses of 120 mg NERLYNX were evaluated in non-cancer patients with chronic hepatic impairment (N = 6 each with Child-Pugh Class A, B and C) and in healthy subjects (N = 9) with normal hepatic function. Neratinib exposures in patients with Child-Pugh Class A (mild impairment) and B (moderate impairment) were similar to that in normal healthy volunteers. In patients with severe hepatic impairment (Child-Pugh Class C), C_{max} and AUC increased by 273% and 281%, respectively, as compared to healthy control subjects.
- **Renal Insufficiency:** In a population pharmacokinetic analysis, NERLYNX clearance among 593 subjects (393 patients and 200 healthy volunteers) showed no relationship with renal function measured as creatinine clearance, which ranged from 30.6 to 213 mL/min/1.73m² in the analysis population. The population included 179 subjects with mild renal impairment (30 to < 60 mL/min/1.73m²) and 37 subjects with moderate renal impairment (60 to < 90 mL/min/1.73m²). NERLYNX has not been studied in patients with severe renal impairment (< 30 mL/min/1.73m²).

There have been no dedicated pharmacokinetic studies in patients with renal impairment or those undergoing hemodialysis.

11 STORAGE, STABILITY AND DISPOSAL

Store at: 15 to 25 °C. Keep bottle tightly closed.
Store in the original package in order to protect from moisture.
Keep in a safe place out of reach and sight of children.

12 SPECIAL HANDLING INSTRUCTIONS

Any unused product or waste material should be disposed in accordance with local requirements.

PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION

Drug Substance


Proper name/Common Name: Neratinib maleate

Chemical name: (E)-N-{4-[3-chloro-4-(pyridin-2-yl methoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl}-4-(dimethylamino)but-2-enamide maleate

Molecular formula: $C_{30}H_{29}ClN_6O_3 \cdot C_4H_4O_4$

Molecular mass: 673.11

Structural formula:



Physicochemical properties:

Neratinib maleate is an off-white to yellow powder with a melting temperature of approximately 201°C, followed immediately by decomposition. The solubility of neratinib maleate increases dramatically in acidic pH. The maximum aqueous solubility of neratinib maleate is 32.90 mg/mL at pH 1.2 and becomes negligible (0.08 mg/mL or less) at approximately pH 5.0 and above.

14 CLINICAL TRIALS

14.1 Clinical Trials by Indication

Extended Adjuvant Treatment of Early-Stage Breast Cancer

Table 16. Summary of Patient Demographics for Clinical Trials in Early-Stage Breast Cancer

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)	Median age (Range)	Sex
ExteNET	Randomized, double-blind, placebo-controlled study in patients with early-stage HER2-positive breast cancer	NERLYNX 240 mg once daily Placebo once daily	2840	52 (23-83)	F: 100%

ExteNET Trial Design and Study Demographics

The safety and efficacy of NERLYNX were investigated in a multicenter, randomized, double blind, placebo-controlled study in women with early-stage HER2-positive breast cancer, who had previously received trastuzumab-based adjuvant therapy (ExteNET).

A total of 2840 women with early-stage HER2-positive breast cancer were randomized to receive either NERLYNX (n = 1420) or placebo (n = 1420). Randomization was stratified by the following factors: hormone receptor status, nodal status (0, 1-3 vs 4 or more positive nodes) and whether prior trastuzumab was given sequentially versus concurrently with chemotherapy. NERLYNX 240 mg or placebo was given orally once daily for one year. The median duration of treatment was 11.6 months in the NERLYNX arm vs. 11.8 months in the placebo arm. Patients who were hormone receptor-positive (defined as ER-positive and/or PgR-positive) received concomitant endocrine therapy.

Patient demographics and disease characteristics were balanced between treatment arms. Overall, patients had a median age of 52 years (range 23 to 83); 12% of patients were 65 years of age or older. The majority of patients were Caucasian (81%), and most (92%) had an ECOG performance status of 0. Fifty-seven percent (57%) had hormone receptor positive disease. At initial diagnosis, 24% were node negative, 47% had one to three positive nodes and 30% had four or more positive nodes. Ten percent (10%) of patients had Stage I disease, 41% had Stage II disease, 31% had Stage III disease and 18% of unknown stage. Median time from diagnosis to randomization was 22.1 months.

Twenty-five percent (25%) of patients had received prior neoadjuvant therapy and 17% initiated trastuzumab in the neoadjuvant setting. The majority of patients (81%) were enrolled within one year of completion of trastuzumab-based adjuvant treatment. Median time from the last adjuvant trastuzumab treatment to randomization was 4.4 months in the NERLYNX arm vs. 4.6 months in the placebo arm.

ExteNET Study Results

The primary efficacy outcome measure was invasive disease-free survival (iDFS) at 24 months defined as the time from randomization to the first occurrence of invasive tumor recurrence (local/regional, ipsilateral, or contralateral breast cancer), distant recurrence, or death from any cause. Secondary endpoints of the study were disease-free survival including ductal carcinoma *in situ* (DFS-DCIS), distant disease-free survival (DDFS), time to distant recurrence (TTDR), and cumulative incidence of central nervous system (CNS) recurrences.

The primary analysis of the efficacy results of the ITT population from the ExteNET study is summarized in Table 17 and a Kaplan-Meier (K-M) plot in Figure 1. The primary analysis demonstrated that NERLYNX significantly reduced the risk of invasive disease recurrence or death at 24 months by 34% (HR = 0.66 with 95% CI: 0.49, 0.90, two-sided p = 0.008) when compared to placebo in the ITT population.

Based on the primary analyses of the secondary endpoints, NERLYNX reduced the risk of DFS-DCIS events by 39% compared to the placebo. A trending benefit was shown for DDFS and TTDR in patients treated with NERLYNX (Table 17). The most frequent site for distance recurrence as DDFS events in NERLYNX-treated patients was bone, followed by liver and brain.

Table 17. Primary Efficacy Analyses at 24 Months – ITT Population

Endpoint	Patient with events (%)		Estimated 2-year event free rates ¹ (%)		Hazard ratio (95% CI) ²	P-value ³
	NERLYNX (N = 1420)	Placebo (N = 1420)	NERLYNX (N = 1420)	Placebo (N = 1420)		
Invasive disease-free survival (iDFS)	4.7	7.5	94.2	91.9	0.66 (0.49, 0.90)	0.008
Disease-free survival including ductal carcinoma <i>in situ</i> (DFS-DCIS)	4.7	8	94.2	91.3	0.61 (0.45, 0.83)	0.001
Distant disease-free survival (DDFS)	3.8	5.4	95.3	94.0	0.74 (0.52, 1.05)	0.094
Time to distant recurrence (TTDR)	3.7	5.3	95.5	94.2	0.73 (0.51, 1.04)	0.087
Cumulative incidence of CNS recurrence	0.8	1.1	0.92	1.16	–	0.548


CNS = central nervous system.

¹ Event-free rates for all endpoints, except for CNS recurrence for which cumulative incidence is reported.

² Stratified by prior trastuzumab (concurrent vs. sequential), nodal status (0-3 positive nodes vs. ≥4 positive nodes), and ER/PR status (positive vs. negative).

³ Stratified 2-sided log-rank test.


Figure 1: Kaplan-Meier iDFS Estimates Primary Analysis at 24 Months – ITT Population



The pre-specified subgroup analyses were performed for the three stratification factors used in randomization (HRc positive vs. HRc negative; nodal disease, prior trastuzumab given sequentially vs. concurrently with chemotherapy), and time from completion of trastuzumab (≤ 1 vs. > 1 year).

A Forest plot of the subgroup analyses of iDFS for the ITT population is shown in Figure 2. In most subgroups analyzed, the treatment effect was in favor of NERLYNX. However, efficacy of NERLYNX (versus placebo) was not demonstrated in patients who were hormone receptor negative ($n = 604$ and 605 , respectively); the hazard ratio for iDFS at 24 months was 0.93 (95% CI: $0.60, 1.43$, $p = 0.365$). Efficacy of NERLYNX (versus placebo) was also not significantly different in patients who were randomized over one year after completion of trastuzumab-based adjuvant therapy ($n = 268$ and 275 , respectively). The hazard ratio for iDFS at 24 months was 0.92 (95% CI: $0.37, 2.23$, $p = 0.430$) in this population.

Figure 2: Forest Plot of Subgroup Analyses of iDFS – ITT population



In an exploratory subgroup analysis for patients who were hormone receptor-positive and less than one year from completion of trastuzumab-based adjuvant therapy, the hazard ratio for invasive disease-free survival was 0.49 (95%CI: 0.30, 0.78). The estimated 2-year event-free rate was 95.3% for NERLYNX arm and 90.8% for placebo arm with a rate difference of 4.5%.

Approximately 75% of the ITT population was re-consented for 5-year follow-up. Observations with missing data were censored at the last date of assessment. This exploratory analysis suggests that the iDFS results at 5 years are consistent with the 2-year iDFS results observed in ExteNET.

Metastatic Breast Cancer

Table 18. Summary of Patient Demographics for Clinical Trials in Metastatic Breast Cancer

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)	Median age (Range)	Sex
NALA	Randomized, open-label, active-controlled study in patients with metastatic,	NERLYNX 240 mg orally once daily + capecitabine 1500 mg/m ² on days 1-14 of a 21-day cycle	621	55 (25-84)	F: 99.5% M: 0.5%

	previously treated, HER2-positive breast cancer	Lapatinib 1250 mg orally once daily + capecitabine 2000 mg/m ² on days 1-14 of a 21-day cycle			
--	---	--	--	--	--

NALA Trial Design and Study Demographics

The safety and efficacy of NERLYNX in combination with capecitabine was studied in a randomized, multicenter, open label clinical trial in patients with metastatic HER2-positive breast cancer who had received 2 or more prior anti-HER2 based regimens in the metastatic setting (NALA).

A total of 621 patients with metastatic breast cancer were randomized 1:1 to receive either NERLYNX in combination with capecitabine or lapatinib in combination with capecitabine. Randomization was stratified by the following factors: number of previous HER2-directed regimens in the metastatic setting, geographical region, visceral versus non-visceral only disease, and hormone receptor status. NERLYNX was given 240 mg orally once daily on Days 1-21 in combination with capecitabine at a total daily dose of 1500 mg/m² evenly divided into 2 doses of 750 mg/m², on Days 1-14 for each 21-day cycle (n = 307). Lapatinib was given 1250 mg orally once daily on Days 1-21 in combination with capecitabine at a total daily dose of 2000 mg/m² evenly divided into 2 doses of 1000 mg/m² on Days 1-14 for each 21-day cycle (n = 314). Patients were treated until disease progression or unacceptable toxicity. The median duration of treatment was 5.7 months in the NERLYNX plus capecitabine arm vs 4.4 months in the lapatinib plus capecitabine arm.

HER2 expression was based on archival tissue tested at a central laboratory prior to enrollment. HER2 positivity was defined as a HER2 immunohistochemistry (IHC) score of 3+ or IHC 2+ with confirmatory in situ hybridization (ISH) positive.

Patients who received previous therapy with capecitabine, neratinib, lapatinib, or any other HER2-directed tyrosine kinase inhibitors and who had symptomatic or unstable brain metastases were excluded from the study. Concomitant endocrine therapy was not allowed in NALA.

Patient demographics and disease characteristics were balanced between treatment arms. Overall, patients had a median age of 55 years (range 25 to 84); 21% of patients were 65 years of age or older. Approximately half of patients were Caucasian (57%), with an ECOG performance status of 0 (54%) or 1 (46%). Fifty-nine percent (59%) of patients had hormone receptor positive disease. At initial diagnosis, 69% had received two prior anti-HER2 based regimens and 31% had received three or more prior anti-HER2 based regimens (99.7% received trastuzumab; 41.7% received pertuzumab; 54.3% received T-DM1; 34.6% received trastuzumab, pertuzumab and T-DM1). 81% had visceral disease, and 19% had non-visceral only disease. Patients with asymptomatic or stable brain metastases were included in NALA trial (16%). Median time from diagnosis to randomization was 3.4 years.

NALA Study Results

The study had two co-primary endpoints: independently adjudicated progression-free-survival (PFS) and overall survival (OS) with success requiring only one to be positive.

The co-primary endpoint of centrally adjudicated progression-free-survival (PFS) was defined as the time interval from the date of randomization until the first date on which recurrence, progression (per RECIST v 1.1), or death due to any cause was documented. The co-primary endpoint of overall survival (OS) was defined as the time from randomization to death due to any cause. Secondary endpoints of the study included objective response rate (ORR), duration of response (DOR), and time to intervention for symptomatic metastatic central nervous system (CNS) disease.

The centrally assessed PFS results for the ITT population from the NALA study is summarized in Table 19 and K-M plots for PFS and OS are presented in Figure 3 and Figure 6, respectively. The primary analysis of PFS demonstrated that NERLYNX plus capecitabine significantly reduced the risk of disease progression or death by 24% (HR = 0.76; 95% CI: 0.63, 0.93; p = 0.0059) when compared to the lapatinib plus capecitabine arm. Median PFS was 5.6 months (95% CI: 4.9, 6.9) in the NERLYNX plus capecitabine arm compared to 5.5 months (95% CI: 4.3, 5.6) in the lapatinib plus capecitabine arm. For OS, the stratified hazard ratio for NERLYNX plus capecitabine was 0.88 (95% CI: 0.72, 1.07; p = 0.2086).

Table 19. Efficacy Results – NALA Trial (ITT Population)


	NERLYNX + Capecitabine (n = 307)	Lapatinib + Capecitabine (n = 314)
Progression Free Survival (PFS)¹		
Number of Events (%)	210 (68.4)	223 (71.0)
Median PFS, month (95% CI)	5.6 (4.9, 6.9)	5.5 (4.3, 5.6)
HR (95% CI)*	0.76 (0.63, 0.93)	
p-value [†]	0.0059	
PFS rates at 12 months, % (95% CI) ^α	29 (23, 35)	15 (10, 20)
PFS rates at 24 months, % (95% CI) ^{‡, α}	12 (7, 18)	3 (1, 8)
Overall Survival (OS)²		
Number of Events (%)	192 (62.5)	218 (69.4)
Median OS, month (95% CI)	21.0 (17.7, 23.5)	18.7 (15.5, 21.2)
HR (95% CI)*	0.88 (0.72, 1.07)	
p-value [†]	0.2086	
Cumulative Incidence of Intervention for Symptomatic Metastatic CNS Disease²		
Overall Cumulative Incidence (95% CI)	22.8 (15.5, 30.9)	29.2 (22.5, 36.1)
Objective Response Rate (ORR)¹		
ORR, % (95% CI)	32.8 (27.1, 38.9)	26.7 (21.5, 32.4)
Complete response (CR)	1 (0.4)	0 (0.0)
Partial response (PR)	83 (32.4)	72 (26.7)
Duration of Response (DOR)¹		
Median DOR, months (95% CI)	8.5 (5.6, 11.2)	5.6 (4.2, 6.4)

HR = Hazard Ratio; CI = confidence interval; CNS = central nervous system

* Hazard ratio is presented as NERLYNX plus Capecitabine (N+C) vs Lapatinib plus Capecitabine (L+C) via the stratified cox proportional hazards model

† Stratified log-rank test
 ‡ The total number of patients remaining on study at 24 months is 11; with 9 patients on N+C and 2 patients on L+C
 α exploratory analysis
 1 Centrally assessed
 2 Locally assessed

Figure 3: Kaplan-Meier Plot of Progression-Free Survival – Central Assessment (ITT Population)




CI = confidence interval; HR = hazard ratio; ITT = intent-to-treat; L+C = lapatinib plus capecitabine; N+C = neratinib plus capecitabine.

Log-rank test and Cox model are stratified by randomization stratification factors: hormone receptor status, number of prior HER2-directed regimens in the metastatic setting, and visceral vs non-visceral only disease location.


In most subgroups analyzed, the treatment effect was in favor of NERLYNX plus capecitabine. However, a statistically significant interaction was found ($p < 0.001$) in the subgroup analysis for PFS by hormone receptor status. The treatment effect in the overall population was substantially driven by hormone receptor-negative patients. The subgroup analyses by hormone receptor status and their respective Kaplan-Meier plots are presented in Figures 4 and 5.

Figure 4: Kaplan-Meier Plot of Progression-Free Survival – Central Assessment (ITT Population, Subgroup: Hormone Receptor Positive)




CI = confidence interval; HR = hazard ratio; ITT = intent-to-treat; L+C = lapatinib plus capecitabine; N+C = neratinib plus capecitabine.

Figure 5: Kaplan-Meier Plot of Progression-Free Survival – Central Assessment (ITT Population, Subgroup: Hormone Receptor Negative)



CI = confidence interval; HR = hazard ratio; ITT = intent-to-treat; L+C = lapatinib plus capecitabine; N+C = neratinib plus capecitabine.

Figure 6: Kaplan-Meier Plot of Overall Survival (ITT Population)



CI = confidence interval; HR = hazard ratio; ITT = intent-to-treat; L+C = lapatinib plus capecitabine; N+C = neratinib plus capecitabine.

Based on OS analysis by subgroup, the hazard ratios (NERLYNX plus capecitabine arm compared to lapatinib plus capecitabine arm) were 0.94 (95% CI: 0.72, 1.22) and 0.76 (95% CI: 0.57, 1.01) in patients with hormone receptor positive and hormone receptor negative status, respectively.

15 MICROBIOLOGY

No microbiological information is required for this drug product.

16 NON-CLINICAL TOXICOLOGY

General Toxicology:

Neratinib was administered orally at doses of 3, 10, and 30 mg/kg/day to rats for 26 weeks. Neratinib-related effects were observed in the liver (hepatic biliary epithelial cell vacuolation) and skin (inflammation) at 30 mg/kg/day, in the intestinal tract (luminal dilatation of the duodenum and ileum, mixed cell inflammation and crypt abscess of the cecum, villous atrophy of the ileum, mixed cell inflammation of the colon) at doses of ≥ 10 mg/kg/day, and in the mammary gland (atrophy) in males and lymph nodes (plasmacytosis, sinus histiocytosis) at doses of ≥ 3 mg/kg/day. Complete or partial recovery was observed for all target organs after a

28-day recovery period. The dose of 3 mg/kg/day in rats was approximately 5 times the maximum recommended human dose of 240 mg/day based on AUC comparison.

Neratinib was administered orally to male and female beagle dogs for at least 39 consecutive weeks at dose levels of 0.5, 2, or 6 mg/kg/day (up to 0.8 times the AUC in patients receiving the recommended dose of 240 mg/day). Neratinib-related microscopic changes were observed in the duodenal papilla (histiocytosis) at 6 mg/kg/day, and in the gall bladder (mucinous hyperplasia, lymphohistiocytic inflammation), mesenteric lymph nodes (sinus erythrocytosis), and testes (tubular hyperplasia) at doses of ≥ 0.5 mg/kg/day. The dose of 0.5 mg/kg/day in dogs was approximately 0.05 times the maximum recommended human dose of 240 mg/day based on AUC comparison.

Carcinogenicity:

Neratinib was not carcinogenic in a 6-month Tg.rasH2 transgenic mouse study at oral doses of up to 50 mg/kg/day in males and 125 mg/kg/day in females (approximately 10-33 times the AUC in patients receiving the recommended dose of 240 mg/day). Similarly, neratinib was not carcinogenic in a 2-year rat study at oral doses up to 10 mg/kg/day (approximately 22-35 times the AUC in patients receiving the recommended dose of 240 mg).

Genotoxicity:

Neratinib and its metabolites M3, M6, M7 and M11 were not mutagenic in an *in vitro* bacterial reverse mutation (AMES) assay or clastogenic in an *in vitro* human lymphocyte chromosomal aberration assay. Neratinib and M3 were not clastogenic in an *in vivo* rat bone marrow micronucleus assay.

Reproductive and Developmental Toxicology:

In a fertility study in rats, neratinib administration up to 12 mg/kg/day (approximately 0.5 times the maximum recommended dose of 240 mg/day in patients on a mg/m² basis) to either males or females caused no effects on mating or the ability of animals to become pregnant. In repeat-dose toxicity studies in dogs with oral administration of neratinib daily for up to 39 weeks, tubular hypoplasia of the testes was observed at ≥ 0.5 mg/kg/day. This finding was observed at AUCs that were approximately 0.05 times the AUC in patients at the maximum recommended dose of 240 mg.

In a fertility and early embryonic development study in female rats, neratinib was administered orally for 15 days before mating to Day 7 of pregnancy, which did not cause embryonic toxicity at doses up to 12 mg/kg/day in the presence of maternal toxicity. A dose of 12 mg/kg/day in rats is approximately 0.5 times the maximum recommended dose of 240 mg/day in patients on a mg/m² basis.

In an embryo-fetal development study in rats, pregnant animals received oral doses of neratinib up to 15 mg/kg/day during the period of organogenesis. No effects on embryo-fetal development or survival were observed. Maternal toxicity was evident at 15 mg/kg/day (approximately 0.6 times the AUC in patients receiving the maximum recommended dose of 240 mg/day).

In an embryo-fetal development study in rabbits, pregnant animals received oral doses of neratinib up to 9 mg/kg/day during the period of organogenesis. Administration of neratinib at doses ≥ 6 mg/kg/day resulted in maternal toxicity, abortions and embryo-fetal death (increased resorptions). Neratinib administration resulted in increased incidence of fetal gross external (domed head), soft tissue (dilation of the brain ventricles and ventricular septal defect), and skeletal (misshapen anterior fontanelles and enlarged anterior and/or posterior fontanelles)

abnormalities at ≥ 3 mg/kg/day. The $AUC_{(0-t)}$ at 6 mg/kg/day and 9 mg/kg/day in rabbits were approximately 0.5 and 0.8 times, respectively, the AUCs in patients receiving the maximum recommended dose of 240 mg/day.

In a peri and postnatal development study in rats, oral administration of neratinib from gestation day 7 until lactation day 20 resulted in maternal toxicity at ≥ 10 mg/kg/day (approximately 0.4 times the maximum recommended dose of 240 mg/day in patients on a mg/m^2 basis) including decreased body weights, body weight gains, and food consumption. Effects on long-term memory were observed in male offspring at maternal doses of ≥ 5 mg/kg/day (approximately 0.2 times the maximum recommended dose of 240 mg/day in patients on a mg/m^2 basis).

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

Pr**NERLYNX**[®]
neratinib tablets

Read this carefully before you start taking NERLYNX and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about NERLYNX.

Your breast cancer may be treated with **NERLYNX** in combination with another medicine (capecitabine). Read the Consumer Information leaflet for capecitabine as well as this one.

What is NERLYNX used for?

NERLYNX is used to treat breast cancer.

- It is used alone to treat adult women whose disease is in an early-stage, when:
 - their cancer cells produce a larger amount of HER2 proteins; and
 - their cancer cells are sensitive to female hormones.

These patients will have had previous treatment with the medicine trastuzumab in the last 12 months.

- It is used in combination with capecitabine to treat adult patients when :
 - their disease has spread to other parts of the body. This is called metastatic disease; and
 - their cancer cells that produce a larger amount of HER2 proteins.

These patients will have previously had their metastatic disease treated with two or more medicines that act on the HER2 protein.

Tests are used to find out if your cancer cells produce large amounts of HER2 proteins and are hormone-sensitive.

How does NERLYNX work?

NERLYNX is a tyrosine kinase inhibitor, which interferes with the growth of certain tumor cells.

What are the ingredients in NERLYNX?

Medicinal ingredients: neratinib (as neratinib maleate)

Non-medicinal ingredients: colloidal silicon dioxide, crospovidone, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, povidone, purified water, talc, titanium dioxide.

NERLYNX comes in the following dosage forms:

Tablets, 40 mg

Do not use NERLYNX if you:

- are allergic to neratinib or any of the other ingredients in this medicine.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take NERLYNX. Talk about any health conditions or problems you may have, including if you:

- have a liver condition
- have a heart condition
- are younger than 18 years of age. The effects of NERLYNX in people younger than 18 years old are not known.
- are older than 60 years of age. This is because NERLYNX may not work as well in older adults whose disease is in an early stage. As well, those who are over 65 years of age are more likely to have side effects.

Other warnings you should know about:

Female patients:

- Avoid becoming pregnant while taking NERLYNX. It may harm your unborn baby or make you lose the pregnancy.
- Use two forms of birth control while you are taking NERLYNX. Keep using these forms of birth control for 1 month after your last dose of NERLYNX.
- Talk to your healthcare professional about birth control methods that may be right for you.
- If you do become pregnant, or think you are pregnant during your treatment with NERLYNX, tell your healthcare professional right away.
- **For women who can get pregnant:** a pregnancy test should be done before you start to take NERLYNX.
- Do not breastfeed while you are taking NERLYNX and for one month after your last dose. It is not known if NERLYNX passes into your breast milk. You and your healthcare professional should decide if you will take NERLYNX or breastfeed.

Male patients:

- Avoid fathering a child while taking NERLYNX.
- Use effective birth control when having sexual intercourse with a female partner who is able to get pregnant. Use these birth control methods while you are taking NERLYNX and for 3 months after your last dose.
- If your partner gets pregnant, tell your healthcare professional right away.

Diarrhea:

Diarrhea (2 or more loose or liquid bowel movements in a day) is a common side effect of taking NERLYNX. It can be severe and cause you to be **dehydrated**, have low blood pressure or **kidney problems**.

To help prevent diarrhea, your healthcare professional may:

Start your treatment with NERLYNX using a lower dose for first two (2) weeks and prescribe another medicine to help prevent diarrhea as needed.

Or

Your healthcare professional may prescribe another medicine to take starting with your first dose of NERLYNX and for the first two months, to help prevent diarrhea.

Your healthcare professional will monitor you for severe diarrhea.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

Some medicines can affect the level of NERLYNX in your body. NERLYNX can also affect the way some other medicines work. When medicines interact with NERLYNX, you may have more side effects. The medicines listed here may not be the only ones that could interact with NERLYNX.

The following may interact with NERLYNX:

- Medicines to lower stomach acid or treat stomach ulcers, such as:
 - medicines called proton pump inhibitors (like lansoprazole),
 - antacids (magnesium-aluminum-hydroxide), or
 - H₂-receptor antagonists (like ranitidine and cimetidine).
- Ketoconazole, itraconazole, fluconazole, posaconazole, voriconazole - used to treat fungal infections.
- Clarithromycin, erythromycin, troleandomycin, ciprofloxacin, rifampin - used to treat bacterial infections.
- Medicines used to boost the effects of other medicines including, ritonavir, lopinavir, nelfinavir, indinavir, saquinavir, tipranavir, cobicistat, boceprevir - used to treat viral infections, including HIV.
- Phenytoin, carbamazepine - used to treat fits (seizures) and epilepsy.
- St John's Wort (*Hypericum perforatum*) - an herbal medicine used mainly for depression.
- Digoxin - used for heart problems.
- Diltiazem, verapamil, dronedarone – used to treat heart conditions or high blood pressure.
- Cimetidine – used to treat stomach problems.
- Idelalisib, crizotinib, imatinib, enzalutamide, mitotane – used to treat other types of cancer.
- Conivaptan – used to treat low sodium levels in blood.
- Dabigatran – used to prevent blood clots.
- Fexofenadine – used to treat symptoms of allergy.
- Nefazodone, fluvoxamine – used to treat depression.
- Tofisopam – used to treat anxiety.
- Aprepitant – used to treat nausea.
- Clotrimazole – used to treat yeast infections.
- Cyclosporine – used after organ transplantation.
- Efavirenz – used to treat HIV and AIDS.

Do not eat or drink any products or juices that contain grapefruit, grapefruit extract. These can affect the way NERLYNX works.

How to take NERLYNX:

NERLYNX will be given to you by a healthcare professional in a healthcare setting.

- Take exactly as your healthcare professional tells you.
- Take once per day with food.
- Take at about the same time each day.
- Swallow tablets whole with a glass of water.
- Do NOT chew, crush or split tablets.

Usual adult dose: 240 mg (six tablets) once a day.

Your healthcare professional may start your dose at 120 mg (three tablets) once a day for the first week of treatment (days 1-7), followed by 160 mg (four tablets) once a day for the second week of treatment (days 8-14), then 240 mg (six tablets) once a day from week 3 (starting on day 15) and onwards.

If you are taking NERLYNX alone for early-stage breast cancer, you may take 240 mg of NERLYNX daily for up to one year.

If you are taking NERLYNX in combination with capecitabine for metastatic breast cancer, your healthcare professional will tell you:

- how long to take NERLYNX, and
- the dose of capecitabine, as well as when and how often to take your capecitabine.

Your healthcare professional may change your dose of NERLYNX, stop your treatment for a short time or stop NERLYNX completely. This will be based on how you are feeling.

Overdose:

If you think you have taken too much NERLYNX, contact your healthcare professional, hospital emergency department or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

If you miss a dose, take your next NERLYNX dose at the next scheduled time. Do not take extra tablets to make up the missed dose.

What are possible side effects from using NERLYNX?

These are not all the possible side effects you may feel when taking **NERLYNX**. If you experience any side effects not listed here, contact your healthcare professional.

Side effects of NERLYNX may include:

- fever
- chills
- flu-like symptoms
- nausea
- constipation
- abdominal pain
- swelling of your abdomen
- upset stomach
- heartburn
- dry or inflamed mouth, or mouth sores

- gas
- hemorrhoids
- loss of appetite
- weight loss
- feeling tired or weak
- muscle spasms
- back pain
- joint pain
- rash
- acne
- nail problems including color change or breakage
- dry skin, skin may crack
- nosebleeds
- runny nose
- nose dryness
- urinary tract infection
- pain or difficulty when urinating
- dizziness

NERLYNX may affect how your liver works. Blood tests will be done before you begin treatment, every month for the first 3 months, and then every 3 months as needed during your treatment with NERLYNX. The results of these tests will help your healthcare professional to check how well your liver is working. Your healthcare professional will stop your treatment with NERLYNX if your blood tests show severe liver problems.

If you experience any of the following signs or symptoms, call your healthcare professional right away. These may be signs that you are having liver problems.

- tiredness
- nausea
- vomiting
- pain in the right upper abdomen
- fever
- rash
- itching
- yellowing of your skin or whites of your eyes

NERLYNX can also cause other abnormal blood test results. Your doctor will decide when to perform other blood tests and will interpret the results.

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
VERY COMMON			
Diarrhea: increased number of stools, loose or watery stools.		X	
Vomiting		X	

COMMON			
Dehydration (loss of too much fluid from the body often due to nausea, vomiting and/or diarrhea, or not taking enough liquids by mouth): thirst, headache, loss of appetite, lack of sweating, decreased urine, low blood pressure, problems with kidney function.		X	
Pneumonia or Pleural Effusion (fluid on the lungs): cough, difficult or painful breathing, wheezing, pain in chest when breathing, fever.		X	
Cellulitis or Erysipelas (serious skin reactions): pain; tenderness; swelling; redness of the skin; painful red, raised patches on the skin, which may be warm to the touch; fever; chills; feeling unwell.		X	
Palmar-plantar erythrodysesthesia syndrome (skin reaction also known as hand-foot syndrome): pain, tingling, swelling or redness, thick calluses and blisters on the palms of the hands or soles of the feet.		X	
Liver injury: yellowing of the skin or the white of your eyes, dark or brown (tea colored) urine, nausea or vomiting, loss of appetite, feeling tired or weak.		X	
UNCOMMON			
Cholelithiasis (gallstones): intense pain in the upper abdomen, pain in right shoulder, nausea, vomiting.		X	
Congestive heart failure or decreased left ventricular ejection fraction (heart does not pump blood as well as it should): shortness of breath, fatigue and weakness, swelling in ankles, legs and feet, cough, fluid retention, lack of appetite, nausea, rapid or irregular heartbeat, reduced ability to exercise.			X
Pancreatitis (inflammation of the pancreas): upper abdominal pain, fever, rapid heartbeat, nausea, vomiting, tenderness when touching the abdomen.		X	
RARE			
Kidney problems: nausea, vomiting, fatigue, changes in how you urinate.		X	

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your healthcare professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

- Keep out of reach and sight of children.
- Store: 15 – 25°C in the original package to protect from moisture. Keep bottle tightly closed.
- Do not take this medicine after the expiry date which is stated on the bottle after “EXP”. The expiry date refers to the last day of that month.
- Do not throw away any unused medicine in the garbage or down the drain or toilet. Ask your pharmacist how to best dispose of medicines that you no longer need. These measures will help to protect the environment.

If you want more information about NERLYNX:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website (<https://www.canada.ca/en/health-canada.html>), the manufacturer’s website (<https://www.gud-knight.com/>), by emailing medinfo@knighttx.com, or by calling 1-844-483-5636.

This leaflet was prepared by Knight Therapeutics Inc.

Last Revised: July 16, 2021